Endocrinology, Diabetes & Metabolism Doctors in New Britain, CT Accepting Medicare

4 Endocrinology, Diabetes & Metabolism doctors found. Showing 1 - 4

Dr. Manmeet Kaur, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 100 Grand St, Joslin Diabetes Center, New Britain, CT 06052 Phone: 860-224-5672

Dr. Ela Banerjee, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 300 Kensington Ave, New Britain, CT 06051 Phone: 860-547-1278    Fax: 860-547-1301

Aashish Gopaldas Samat, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 100 Grand St, New Britain, CT 06052 Phone: 860-224-5672    Fax: 860-224-5956

Dr. William A. Petit Jr., MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 100 Grand St, Ondrea Chasse, Medical Staff Office, New Britain, CT 06052 Phone: 860-224-5305

News Archive

Linkam Launches New Water Circulation Pump to Optimise Cooling of its Temperature Control Stages

New Water Circulation Pump, designed to provide optimized water cooling to its range of temperature and environmental control stages from Linkam.

Council for American Medical Innovation mourns the death of Senator Edward M. Kennedy

The Council for American Medical Innovation joins with members of the health community in mourning the loss of Senator Edward M. Kennedy, one of America's foremost advocates for all health care causes, particularly the medically underserved. His work in advancing medical innovation has left an indelible mark on the innovation space and transformed America's ability to invest in cures for illnesses that affect patients around the world.

Cell Therapeutics' NDA for Pixantrone accepted by the FDA

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.

UC biophysicist develops useful instruments that can advance diagnosis, treatment of debilitating conditions

Necessity is the mother of invention, and nowhere does that aphorism apply more than in the realm of humans and their physical needs.

IntegenX to accelerate commercialization of human DNA identification system with SV acquisition

IntegenX Inc., a privately held company that is a leader in the emerging field of rapid human DNA identification, today announced that it has acquired SV Corp, a wholly owned subsidiary of GE Healthcare Bio-Sciences. IntegenX will leverage SV Corp's products and intellectual property assets to expand its consumables offering and to accelerate the commercialization of its RapidHIT 200 Human DNA Identification System.

Read more Medical News

› Verified 9 days ago